Clinical Trials Logo

Clinical Trial Summary

- Collect a large number of samples with certain / suspected diagnosis of collecting duct carcinoma in order to confirm the diagnosis (centralized review) and standardize according to WHO 2016 criteria - Build an extensive tissue bank (DNA and RNA extraction) aimed at defining the molecular taxonomy of the tumor through 1) transcriptomic analysis 2) gene expression profile - Define specific molecular signatures


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05372302
Study type Observational
Source Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact Elena Verzoni, MD
Phone 0223904449
Email elena.verzoni@istitutotumori.mi.it
Status Recruiting
Phase
Start date July 8, 2021
Completion date October 2022

See also
  Status Clinical Trial Phase
Withdrawn NCT04603365 - Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer Phase 2
Not yet recruiting NCT06302569 - Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma Phase 2
Recruiting NCT03866382 - Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Phase 2
Recruiting NCT04071223 - Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study Phase 2
Not yet recruiting NCT06211114 - Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma Phase 2